Editors Choice

The New COVID Variant — A Striking Symptom You Should Know About

While he lived over four centuries ago, Shakespeare’s words still ring true, even regarding today’s global coronavirus pandemic. At his birth in 1564, the playwright’s hometown of Stratford upon Avon was visited by the plague, carried by fleas living on rats’ fur.

Moreover, Shakespeare witnessed numerous waves of the plague, with the disease taking the lives of hundreds of thousands of Europeans in his lifetime. With each plague outbreak in England, rulers banned mass gatherings, including London theater performances.

From 1603 to 1613, when Shakespeare’s powers as a writer peaked, the Globe and other London theatres were closed for a remarkable 78 months or over 60 percent of the time.

“Pursue him to his house, and pluck him thence:
Lest his infection, being of catching nature,
Spread further.”

Coriolanus Act 3, Scene 1

What is the New COVID Variant Arcturus (XBB.1.16)?

Arcturus, also known as XBB.1.16, is a subvariant of the Omicron variant of SARS-CoV-2. It was first identified in India in January 2023 and has since been detected in over 30 countries.

Arcturus is thought to be more transmissible than previous variants of Omicron, but there is no evidence that it is more severe.

Many of the symptoms of Arcturus are similar to those of other variants of COVID-19. They may include fever, cough, shortness of breath, fatigue, muscle aches, headache, sore throat, congestion, runny nose, and loss of taste or smell.

Some people may experience gastrointestinal symptoms like nausea, vomiting, and diarrhea.

But there is one atypical symptom associated with the Arcturus: Itchy eyes. Dr. Matthew Binnicker, director of the Clinical Virology Laboratory at Mayo Clinic (USA), offers:

“One new feature of cases caused by this variant is that it seems to be causing conjunctivitis, or red and itchy eyes, in young patients. This is not something that we’ve seen with prior strains of the virus.”

Is Arcturus Especially Dangerous?

While COVID-19 rates in the U.S. are relatively low and are declining, the World Health Organization (WHO) is keeping an eye on a new COVID-19 variant.

The WHO has listed the omicron subvariant XBB.1.16, known as “Arcturus,” as a variant under monitoring since March 22. Experts say this variant has a higher transmissibility rate than previous strains but doesn’t appear more dangerous.

“He shall not breathe infection in this air” — Henry VI Part 2, Act 3, Scene 2

The New COVID Variant (Arcturus) management

There is no specific treatment for Arcturus, but the same treatments that are effective against other variants of COVID-19 may also be effective against Arcturus. These treatments include:

  • Vaccination. The COVID-19 vaccines prevent serious illness, hospitalization, and death from Arcturus.
  • Paxlovid. Paxlovid is an antiviral medication that is effective against Arcturus. It is recommended for people at high risk of serious illness from COVID-19.
  • Monoclonal antibodies. Monoclonal antibodies are a type of antibody that can be given to people who are at high risk of serious illness from COVID-19. They are not as effective as Paxlovid, but they may be an option for people who cannot take Paxlovid.

“The miserable have no other medicine, but only Hope.” — Measure for Measure, Act 3, Scene 1

The best way to protect yourself from Arcturus is to get vaccinated and boosted. You should also wear a mask in public indoor settings, practice social distancing, and wash your hands frequently.

Although COVID-19 rates in the U.S. are relatively low, health experts recommend people remain continue to use risk-reducing tactics, including the following:

  • Wash your hands frequently.
  • Avoid close contact with people who are sick.
  • Stay home if you feel sick or have any symptoms of COVID-19.

I hope you learned something about the COVID variant with the epic name.

Michael Hunter, MD

I received an undergraduate degree from Harvard, a medical degree from Yale, and trained in radiation oncology at the University of Pennsylvania. I practice radiation oncology in the Seattle area.

Recent Posts

How Real-World Evidence Proves the Power of Patient Engagement

Data isn’t just an asset—it’s a trust marker. In life sciences, our credibility hinges on…

2 days ago

This 5-Minute Habit Could Help Prevent a Dangerous Heart Condition.

At 7:28 a.m., the sidewalk was still damp from last night’s Seattle area rain. I…

4 days ago

How the growing trade war could affect biopharma intellectual property

President Trump said recently that the United States will announce a “major” tariff on pharmaceutical…

6 days ago

STOP! Brushing Your Teeth May Expose You to Deadly Neurotoxins

Are you sure the toothpaste you’re using is safe and won’t expose you or your…

6 days ago

‘They Won’t Help Me’: Sickest Patients Face Insurance Denials Despite Policy Fixes

In 2023, Sheldon Ekirch was diagnosed with small fiber neuropathy, which makes her limbs and…

6 days ago

A Digital Turning Point in Migraine Care: CT-132 FDA Approval to Market is a Win for Patients and Proof that Clinical Evidence Matters

First Digital Health App United States Approval for Migraine Treatment with a Comprehensive Indication of…

2 weeks ago

This website uses cookies. Your continued use of the site is subject to the acceptance of these cookies. Please refer to our Privacy Policy for more information.

Read More